USA flag logo/image

An Official Website of the United States Government

Drugs Targeting Dormant Tumors as Anti-Metastatic Agents

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88958
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA135867
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
DORMATARG, INC.
3117 CASTLEROCK RD OKLAHOMA CITY, OK 73120-1817
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
Agency: HHS
Contract: 1R43CA135867-01
Award Amount: $122,450.00
 

Abstract:

DESCRIPTION (provided by applicant): Most cancer deaths occur from metastatic tumors rather than from the primary tumor alone. Although many of the new drugs in the past decade are directed against tumors , changes in overall cancer survival have only been modest. Most cures of cancer are still through surgery and early detection, with chemotherapeutic agents simply delaying the inevitable and buying the patient some number of months or years of life of varying quality. Yet, the drug screening and clinical trial paradigms are aimed at identifying drugs that shrink primary tumors with efficacy against metastatic disease emerging only fortuitously. The overall hypothesis of this project is that a novel drug screening approach using metastatic cancer cells sup pressed by a local microenvironment would yield drugs that are preferentially active against dormant micrometastases, leading ultimately to drugs active against metastases. We used a medium throughput screening system and a chemical library to identify thr ee candidate compounds - Bordeaux Red (BDR), Wool Violet 2R (WV) and 3,4,5,6-tetrabromofluorescein (TBF) which have significant anti-proliferative selectivity against suppressed bladder, prostate, breast, glioma and gastric tumor cells grown on a normal su ppressive matrix called SISgel as compared to their actively growing counterparts on Matrigel. Further, in a human bladder cancer flank xenograft implant model, we have shown that metronomic dosing of all three candidate agents as monotherapy is capable of decreasing the size of suppressed tumors and that one of these compounds, TBF, is also capable of significantly reducing the growth rate and perhaps the vascularity of an actively growing colon xenograft. In the first specific aim, we seek to determine wh ether our three candidate compounds are active against two additional tumor xenograft models, MDA-MB-435 metastatic breast and DU145 metastatic prostate cells, injected into the flank of athymic mice either in the suppressive matrix SISgel or on the permis sive matrix Matrigel, with primary tumor growth and tumor vascularity assessed. In the second specific aim the effect of our three candidate compounds on the formation lung metastases, primary tumor growth, and tumor vascularity in the orthotopically impla nted MDA-MB-435 breast model will be assessed. Together these studies will give proof of principle that our candidate compounds are active against suppressed as compared to activated metastatic tumors in vivo and whether our agents can be used to prevent m etastases, which currently often end up leading to patient death. This proof of principle represents an essential element in our business plan by connecting cell culture studies with animal models of human cancer. PUBLIC HEALTH RELEVANCE: Most cancer death s are not due to the primary tumor but are due to metastatic tumors, many of which lie dormant for years while remaining resistant to chemotherapy. We believe that many of these recurrences are due to cancer cells that have been suppressed by a normal extr acellular matrix, the floor that cells grow on. Research in our laboratories have developed a novel screening system that identifies drugs that potentially can kill dormant cancer cells. This study is seeking to prove that the killing activity seen in ce ll culture occurs in animal models of cancer, which will establish proof for our business model.

Principal Investigator:

Business Contact:


rhurst@coxconnect.net
Small Business Information at Submission:

DORMATARG, INC.
DORMATARG, INC. 3117 CASTLEROCK RD OKLAHOMA CITY, OK 73120

EIN/Tax ID: 101089428
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No